Cell Bio Human Tech Terminates Treasury Stock Acquisition Trust After Acquiring 74,956 Shares… Shareholder Value Enhancement Buyback Completed
Cell Bio Human Tech decided to terminate its treasury stock acquisition trust agreement with DAISHIN Securities, originally valued at 500 million KRW, after fully acquiring the target of 74,956 shares. The termination date is June 9, 2026.
With this acquisition, the company's treasury stock increased from 961,765 to 1,036,721 shares, representing 11.10% of total outstanding shares. Among these, 961,765 shares are designated for exchangeable bonds and will be disposed upon exercise of conversion rights.
Additionally, the company completed the cancellation of 3,688 common shares on May 4, 2026, following a resolution at the 11th regular shareholders' meeting, which reduces outstanding shares and enhances shareholder value.
While the termination of the trust and completion of share buybacks may support short-term stock price stability, the large treasury stock holdings and outstanding exchangeable bonds pose potential dilution risks when conversion rights are exercised, warranting investor caution.
[AI Summary]Cell Bio Human Tech completed a 500 million KRW share buyback and terminated the related trust agreement, acquiring about 0.8% of outstanding shares. Combined with existing holdings, total treasury stock reaches 11.10%, preventing dilution. However, potential conversion of exchangeable bonds and high treasury levels may pressure the stock, leading to a neutral assessment.
KOSDAQ Filing Information
Report on Major Matters (Decision on Termination of Trust Agreement for Acquisition of Treasury Shares)